Table 1.
Patient’s characteristics.
| Pat.ID | Resection status | MGMT* met % | Site of primary | N° of vaccine cycle (I/M) | DTH test H/KLH § |
|---|---|---|---|---|---|
| #0001 | subtotal | 53% | F-P lobe | 4/1 | 0/++ |
| #0002 | subtotal | 22% | T-O lobe | 4/5 | +/+++ |
| #0003 | subtotal | 21% | F-T lobe | 4/2 vial shortage | 0/0 |
| #0004 | gross | 0 | P lobe | 4/2 vial shortage | 0/0 |
| #0005 | subtotal | 13% | F Lobe | 4/1 | 0/+ |
| #0006 | gross | 0% | T lobe | 4/5 | 0/++ |
| #0007 | gross | 49% | F lobe | 3/0 vial shortage | 0/0 |
| #0008 | gross | 0% | F lobe | 4/8 | 0/0 |
| #0009 | subtotal | 0% | T lobe | 4/5 vial shortage | 0/+++ |
MGMT met, MGMT methylation; F, frontal; P, parietal; T, temporal; I/M induction/Maintenance; DTH, delayed-type hypersensitivity; H, Homogenate; KLH, Keyhole limpet hemocyanin; * tested by Pyrosequencing § at baseline DTH test was negative for both H and KLH in all nine patients.
The diameter of induration/erythema observed after 24 hrs is recorded according to the following scale: 0-5 mm grade 1 (+), 6-10 mm grade 2 (++), 11-20 mm grade 3 (+++), > 21 mm grade 4 (++++).